Table 1.
Characteristics of participants by HIV status.
| HIV+ (n = 296) | HIV- (n = 215) | ||
| n (%) or median (IQR)/mean ± SD | P value | ||
| Age (years) | 48.48 (34.56–55.34) | 38.36 (29.20–50.45) | <0.0001 |
| Female sex | 74 (14.48) | 86 (16.63) | 0.0002 |
| Nonwhite racea | 197 (38.55) | 62 (11.99) | <0.0001 |
| BMI (kg/m2) | 26.4 (23.47–32.02) | 26.68 (23.09–30.58) | 0.71 |
| Current smoker | 157 (30.78) | 134 (25.97) | 0.02 |
| ARV duration (months) | 119.53 ± 80.87 | – | – |
| HIV duration (months) | 167.11 ± 104.91 | – | – |
| Family history of MI | 79 (15.46) | 53 (10.25) | 0.83 |
| Current CD4+ cell count | 711 (525–911) | – | – |
| Nadir CD4+ cell count | 222 (83.5–334) | – | – |
| HOMA-IR | 2.37 (1.25–3.75) | 1.98 (1.33–2.96) | 0.02 |
| Cholesterol (mg/dl) | 169 (143–192) | 171.00 (148.00–198.00) | 0.19 |
| LDL (mg/dl) | 90 (71–113) | 98.00 (78.00–121.00) | 0.01 |
| HDL (mg/dl) | 47 (39.9–58) | 49.00 (42.00–58.20) | 0.12 |
| Triglycerides (mg/dl) | 104 (76–162) | 95.00 (68.00–139.00) | 0.02 |
| Ox LDLb | 45.24 (35.29–58.47) | 43.58 (33.84–54.16) | 0.07 |
| Current NRTI | 268 (90.54) | – | – |
| Current NNRTI | 86 (29.05) | – | – |
| Current PI | 82 (27.70) | – | – |
| IL-6 (pg/ml) | 2.3 (1.39–3.53) | 2.33 (1.26–4.15) | 0.84 |
| VCAM (ng/ml) | 777.23 (640.15–936.55) | 768.11 (602.07–931.38) | 0.15 |
| hs-CRP (ng/ml) | 2233.39 (932.45–6062.38) | 2495.51 (915.95–5477.27) | 0.47 |
| D-dimer (ng/ml) | 329.63 (223.16–541.74) | 379.40 (234.74–629.09) | 0.41 |
| IFAB (pg/ml) | 2049.47 (1351.17–3527.09) | 1573.71 (1094.64–2372.43) | <0.0001 |
| LBP (ng/ml)b | 17.02 (11.92–25.47) | 17.73 (13.26–24.83) | 0.63 |
| sCD14 (ng/ml) | 1691.42 (1322.9–2138.64) | 1653.35 (1374.82–2036.00) | 0.47 |
| sCD163 (ng/ml) | 673.84 (480.37–1037.96) | 657.37 (459.85–999.93) | 0.29 |
ARV, antiretroviral; BMI, body mass index; HDL, high-density lipoprotein; hs-CRP, high-sensitivity C-reactive protein; HOMA-IR, homeostatic model assessment of insulin resistance; IFAB, intestinal fatty acid binding protein; IL-6, interleukin 6; IQR, interquartile range; LBP, lipopolysaccharide-binding protein; LDL, low-density lipoprotein; MI, myocardial infarction; NNRTI, non-nucleoside reverse transcriptase inhibitors; NRTI, nucleoside reverse transcriptase inhibitors; Ox LDL, oxidized low-density lipoprotein; PI, protease inhibitor; sCD14; soluble CD14; sCD163, soluble SD163; SD, standard deviation; VCAM, vascular cell adhesion molecule.
Includes African American, Asian, Hispanic, and others.
Per 1000.